Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc; and Merck & Co, Inc.

Community Practice Connections™: Perspectives on PARP, HER2/3, and Emerging Oncogenic Targets in Breast Cancer Care

Release Date: May 29, 2020
Expiration Date: May 29, 2021

Activity Overview

This online education activity is designed to provide expert commentary regarding the latest clinical data on poly (ADP-ribose) polymerase (PARP), human epidermal growth factor receptor 2/3 (HER2/3), and phosphatidylinositol-3-kinase (PI3K) inhibitors as well as potential applications for investigational oncogene-targeted therapies in breast cancer. This program also includes treatment based on mutation status and strategies to overcome primary or acquired resistance to first-line targeted therapies, which drives the need for novel, more effective targeted and combination therapies, such as PI3K inhibitors, bispecific antibodies, dual inhibitors, and antibody-drug conjugates. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Support

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc; and Merck & Co, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate the mechanistic rationale for developments in PARP inhibition, HER2/3 inhibition, and PI3K inhibition in breast cancer
  • Analyze targeted treatment strategies in appropriate patients with breast cancer based on patient characteristics and genetic markers
  • Recognize mechanisms of resistance in breast cancer and emerging strategies for management of resistance using combination strategies that include targeted therapies
  • Evaluate emerging roles for PARP inhibitors, HER2/3 inhibitors, and PI3K inhibitors in breast cancer based on ongoing clinical trials

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Mark E. Robson, MD
Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician, Breast Medicine and Clinical Genetics Services
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Paid to Institution: AbbVie, AstraZeneca, Invitae, Medivation, Myriad, Pfizer, Tesaro; Consultant: AstraZeneca, McKesson, Merck (uncompensated); Other: Travel: AstraZeneca.

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosures: Grant Research Support: Ambrx, Amgen, Arvinas, Bayer, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Genentech, GlaxoSmithKline, Eli Lilly, Immunomedics, MacroGenics, Medivation, Merrimack Pharmaceuticals, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Seattle Genetics; Travel: Eli Lilly, Novartis, OBI Pharma.

Daniel S. O'Neil, MD, MPH
Daniel S. O'Neil, MD, MPH
Assistant Professor of Clinical Medicine
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, FL

Disclosures: Daniel S. O'Neil, MD, MPH, has no relevant financial relationships with commercial interests.

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Novartis, Polyphor; Consultant: AstraZeneca, Genomic Health, GlaxoSmithKline, Novartis, Pfizer.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By